Scienmag

JANUARY 8, 2021

Dill/NIST In a technique known as DNA origami, researchers fold long strands of DNA over and over again to construct a variety of tiny 3D structures, including miniature biosensors and drug-delivery containers.

DNA 95

DNA Drug Delivery Containment Research 95

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). Within the past year, the sector saw the EU’s landmark approval of the first allogeneic T cell therapy as well as the approval of several new gene therapies in the US.

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. About the ISPE Facility of the Year Awards Program.

Manufacturing 52

Manufacturing Packaging Packaging Production 52

The Pharma Data

MARCH 4, 2021

Our work together demonstrates the strength of Takeda’s partnership model and our commitment to delivering transformative medicines to patients with neurological diseases.”. Dravet syndrome is most commonly caused by a genetic mutation in the SCN1A gene and affects approximately 1 in 15,000 to 1 in 21,000 people in the United States.

Development 52

Development Containment Medicine Clinical Trials 52

The Pharma Data

MAY 6, 2021

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. For more information, visit [link].

Containment 52

Containment Production Development Engineer 52

XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. Suri, as the company’s approach is “a very unique marriage between very rational protein engineering and immunology.”.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

APRIL 18, 2022

Hyperimmune globulin : Takeda co-founded the CoVIg-19 Plasma Alliance and joined forces with other leading plasma companies to evaluate a hyperimmune globulin medicine in a global clinical trial. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience and Gastroenterology (GI).

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52

The Pharma Data

JULY 27, 2021

Amgen’s R&D resources and its extensive clinical experience in immuno-oncology are ideally suited to applying and advancing Teneobio’s differentiated technologies and multispecific antibodies to deliver transformative medicines,” said Roland Buelow, Ph.D., chief executive officer of Teneobio.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

This disease is a debilitating form of genetic epilepsy in children that significantly impacts movement, motor control, cognition and quality of life, and there remains a need to alter the course of this disease early in life.”. Assistant Professor in Pediatric Neurology at UT Southwestern. About Taysha Gene Therapies.

Gene Therapy 52

Gene Therapy Gene Drugs Production 52

XTalks

DECEMBER 13, 2023

These efforts encompass programs related to the shingles vaccine, Tdap vaccine and plague vaccine, reinforcing Dynavax’s commitment to advancing the field of vaccines and medicine. The year 2022 has proven to be a momentous period for Fulgent Genetics, marked by significant expansion of its product portfolio across various medical conditions.

Genetics 111

Genetics Vaccination Vaccine DNA 111

The Pharma Data

SEPTEMBER 8, 2020

(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Cambridge, UK.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

APRIL 27, 2021

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI).

Drugs 52

Drugs FDA Approval Production Trials 52

The Pharma Data

DECEMBER 20, 2020

China is an important market for Takeda in our efforts to accelerate the availability of our highly innovative medicines to patients living with complex and rare diseases,” said Ricardo Marek, President, Growth & Emerging Markets Business Unit, Takeda. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Sales 40

Sales Production Marketing Containment 40

pharmaphorum

JANUARY 3, 2023

Haemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one or several blood clotting factors. SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene.

Gene Therapy 98

Gene Therapy Gene Medicine Trials 98

Roots Analysis

SEPTEMBER 18, 2023

Due to the infrastructure available for processing, freezing and storing of these container systems, blood bags are the preferred container for cell therapy biopreservation. The above figure presents a general overview of the cryopreservation process.

Engineer 52

Engineer Containment In-Vivo Production 52

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Synthetic libraries for antibody drug discovery .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

AUGUST 10, 2022

Finally, in 2017, after years of improving T cell engineering techniques, the first chimeric antigen receptor (CAR) T cell therapy received FDA approval. Cells from solid tumours are genetically heterogeneous both between and within tumours, making it challenging to identify a single, selective antigen target for treatment.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

DECEMBER 15, 2022

Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced short palindromic repeat (CRISPR) nucleases have been heralded for their enormous potential to treat diseases and genetic disorders. Likewise, Lessard et al.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

The Pharma Data

JULY 6, 2021

The STASEY study is one of the largest open-label studies primarily assessing the safety and tolerability of a medicine for adults and adolescents with haemophilia A with factor VIII inhibitors. At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 27, 2023

Genetic insights are also guiding healthcare closer to precision medicine, enabling clinicians to tailor medical decisions or therapies to each patient. However, this quantum leap in bioscience comes with the challenge of how to store and manage large volumes of sensitive patient data.

Genome 52

Genome Genomics Research Scientist 52

The Pharma Data

DECEMBER 8, 2020

Takeda has built a world-class, state-of-the-art R&D engine and has generated a diverse and dynamic pipeline of approximately 40 clinical-stage new molecular entities that is beginning to deliver. TAK-003 is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.

Containment 52

Containment Engineer FDA Approval Vaccination 52

The Pharma Data

JANUARY 18, 2021

oncolytic virus (VVcopTK-RR-), and has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR®/F.I.R.S.T From this, BT-001 is engineered to encode both a highly differentiated Treg depleting anti-CTLA4 antibody and the human GM-CSF cytokine. .

Trials 40

Trials Antibody Engineer Clinical Trials 40

Drug Discovery World

JUNE 14, 2023

If a donor already has a part of a profile you were expecting to engineer, that can limit the risks, time and costs associated with target cell modification. Besides looking at donor characteristics, our platform, which we call Excellos 360TM, includes the assessment of metabolic and effector potential of cells, and genetic analysis.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

Drug Discovery World

AUGUST 15, 2023

The roles of individual mechanisms of electrophysiological fractionation analysis have also been studied in animal models in ferrets, rabbits and mice, which can be manipulated pharmacologically or genetically to illustrate relevant pathophysiological mechanisms. Communications Medicine, 2(1), Article 1: 1-16. Heart Rhythm 3(7): 771-8.

Drugs 52

Drugs In-Vivo Development Research 52

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. Internal Medicine. approval in 2021.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

MAY 14, 2021

I was doing research and development for a telecommunications company, where I worked as a senior computer engineer. I’d been working in engineering for about 5 years, but I was feeling a calling to pursue a career in the fitness industry. This ebook contains the entire plan in an easy to follow manner! arms, yet I’m only 5, 5”.

Production 52

Production Branding Engineer Vaccination 52

The Pharma Data

MAY 13, 2021

Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease. The Yale Journal of Biology and Medicine. Preventive Medicine Reports. Fructose-containing sugars, blood pressure, and cardiometabolic risk: a critical review.

Insulin 52

Insulin Production Hormones Medicine 52

pharmaphorum

JANUARY 4, 2023

Because these products can be efficiently manufactured in large batches, the approach eases some of the challenges associated with autologous cell therapies (in which a patient’ cells are collected, genetically modified, and then returned to the patient) and offers the potential to accelerate time to therapy and broaden access globally.

Gene Therapy 98

Gene Therapy Manufacturing Gene Production 98

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. CanSino Biologics is developing a vaccine that involves snipping a bit of the virus’ genetic code off and coupling it with a harmless virus to provoke a SARS-CoV-2 immune response. Brazil has the second worst outbreak in the world, as it is now reporting over 1.8

Vaccination 92

Vaccination Vaccine Antibody Life Science 92